- Home
- JKHY vs ARWR Comparison
JKHY vs ARWR Comparison
Compare JKHY & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | ARWR |
|---|---|---|
| Founded | 1976 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 12.4B |
| IPO Year | 2000 | 2009 |
Fundamental Metrics
Financial Performance| Metric | JKHY | ARWR |
|---|---|---|
| Price | $161.30 | $83.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $197.25 | $83.40 |
| AVG Volume (30 Days) | 903.5K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | 11.86 | ★ 99.80 |
| EPS | ★ 6.98 | N/A |
| Revenue | ★ $1,536,603,000.00 | $16,142,321.00 |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $6.39 | N/A |
| P/E Ratio | $22.70 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $121.04 | $28.12 |
| 52 Week High | $193.39 | $95.49 |
Technical Indicators
Market Signals| Indicator | JKHY | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 43.60 |
| Support Level | $153.74 | $82.05 |
| Resistance Level | $162.07 | $84.55 |
| Average True Range (ATR) | 3.92 | 2.95 |
| MACD | -1.54 | -0.62 |
| Stochastic Oscillator | 19.32 | 25.60 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.